Description
SOHONOS (palovarotene) capsules
The U.S. Food and Drug Administration (FDA) has approved Sohonos (palovarotene) capsules for reduction in the volume of new heterotopic ossification (extra-skeletal bone formation) in adults and children aged 8 years and older for females, and 10 years and older for males with fibrodysplasia ossificans progressiva. Sohonos is the first drug approved for patients with fibrodysplasia ossificans progressiva.
Fibrodysplasia ossificans progressiva is a rare, autosomal dominant disease where connective tissue such as muscle, tendons and ligaments gradually turn into bone tissue, causing limited movement, deformities and severe disability.
Get Access to SOHONOS (palovarotene) capsules In India
On request it available to patient and doctors. Medvitaz Pharma is equipped to facilitate the distribution of SOHONOS (palovarotene) capsules (prescription medications) worldwide and throughout India upon completion of necessary legal procedures, if applicable.
To inquire about the price of either the branded medication “SOHONOS (palovarotene) capsules” or the generic version “palovarotene capsules” for personal use under patient-specific treatment in various cities including Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim, and others in India, please fill out the request form. Upon receiving your request and assessing the delivery process, we will provide you with an estimated price for the medication within 24 hours.
For any inquiries or assistance, please reach out to our Patient Support Team. We are available to assist you from Monday to Friday, between 9:00 and 19:00 IST. You can contact us via email at [email protected], toll-free at +91 8750295029, or through WhatsApp at +91-8750295029.
References
- Spevigo approved for expanded indications in China and the US. News release. Boehringer Ingelheim. March 19, 2024. Accessed March 19, 2024. https://www.boehringer-ingelheim.com/us/spevigo-approved-expanded-indications-china-and-us
- Morita A, Strober B, Burden D, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. September 19, 2023. Accessed March 19, 2024. DOI:https://doi.org/10.1016/S0140-6736(23)01378-8PlumX Metrics
- FDA approves the first treatment option for generalized pustular psoriasis flares in adults. News release. Boehringer Ingelheim. September 1, 2022. Accessed March 19, 2024. https://www.boehringer-ingelheim.com/us/press-release/fda-approves-first-treatment-option-generalized-pustular-psoriasis-flares-adults